<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21850" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Fluoxetine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sohel</surname>
            <given-names>Ahsan J.</given-names>
          </name>
          <aff>University of California, Los Angeles</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shutter</surname>
            <given-names>Mollie C.</given-names>
          </name>
          <aff>Loyola</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Molla</surname>
            <given-names>Mohammed</given-names>
          </name>
          <aff>Kern Medical</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ahsan Sohel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mollie Shutter declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohammed Molla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21850.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Fluoxetine is an FDA-approved medication that has demonstrated efficacy in treating a spectrum of psychological conditions. These indications&#x000a0;include major depressive disorder, obsessive-compulsive disorder, panic disorder, bulimia, binge eating disorder, premenstrual dysphoric disorder, and bipolar depression, including cases of treatment-resistant depression when combined with olanzapine. The mechanism of action involves the inhibition of serotonin reuptake in presynaptic neurons, achieved by blocking the reuptake transporter protein. This activity provides insights into fluoxetine's indications, off-label uses, mechanism of action, dosing, adverse effects, contraindications, monitoring, and toxicity.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify potential indications for fluoxetine therapy based on evidence-based guidelines and patient-specific factors.</p></list-item><list-item><p>Screen patients for contraindications, comorbidities, and potential drug interactions before initiating fluoxetine therapy.</p></list-item><list-item><p>Apply evidence-based strategies to manage and mitigate common side effects associated with fluoxetine, such as gastrointestinal symptoms, sexual dysfunction, and weight changes.</p></list-item><list-item><p>Select alternative treatment options or adjust dosages when necessary based on patient response, tolerability, drug interactions, and treatment-resistant symptoms.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21850&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21850">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21850.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Fluoxetine has received FDA approval&#x000a0;to treat major depressive disorder (8 and older), obsessive-compulsive disorder (7 and older), panic disorder (with or without agoraphobia), bulimia nervosa, depressive episodes associated with Bipolar I disorder (as an adjunct with olanzapine), and treatment-resistant depression when used in combination with olanzapine.<xref ref-type="bibr" rid="article-21850.r1">[1]</xref><xref ref-type="bibr" rid="article-21850.r2">[2]</xref><xref ref-type="bibr" rid="article-21850.r3">[3]</xref>&#x000a0;</p>
        <p>The American Psychiatric Association guidelines recommend fluoxetine as first-line pharmacotherapy (along with CBT) for patients with bulimia nervosa.<xref ref-type="bibr" rid="article-21850.r4">[4]</xref>&#x000a0;</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Non-FDA-approved uses for fluoxetine include binge eating disorder, social anxiety disorder, premenstrual dysphoric disorder, borderline personality disorder, Raynaud phenomenon, and selective mutism.<xref ref-type="bibr" rid="article-21850.r5">[5]</xref><xref ref-type="bibr" rid="article-21850.r6">[6]</xref>&#x000a0;</p>
        <p>The&#x000a0;American Psychological Association endorses fluoxetine for post-traumatic stress disorder (PTSD).<xref ref-type="bibr" rid="article-21850.r7">[7]</xref></p>
      </sec>
      <sec id="article-21850.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Serotonin and norepinephrine, both biological amines, have been shown to play a role in the treatment of depression. Low concentrations of serotonin appear in the cerebrospinal fluid of patients with depression. Additionally, lower numbers of serotonin uptake sites are located on the platelets of patients with depression. Presynaptic serotonin (5-HT1A) receptors are located in the dorsal raphe nucleus, which project to the prefrontal cortex. Fluoxetine exerts its antidepressant effects by blocking the reuptake of serotonin in the presynaptic serotonin neurons by blocking the reuptake transporter protein in the presynaptic terminal. Fluoxetine also has mild activity at the 5-HT2A and 5-HT2C receptors.</p>
        <p>Fluoxetine has minimal activity on noradrenergic reuptake. Due to the drug's&#x000a0;action on the reuptake of serotonin, fluoxetine produces an activating effect, and due to its long half-life, the initial antidepressant effect emerges within 2 to 4 weeks.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Peak plasma concentrations of fluoxetine are attained after 6 to 8 hours. Fluoxetine is well absorbed with a bioavailability of 70% to 90%. Food does not appear to impact the bioavailability of fluoxetine, but it may slow its absorption by 1 to 2 hours, which is not clinically significant. Thus, fluoxetine may be administered with or without food.</p>
        <p><bold>Distribution:</bold> Fluoxetine has plasma protein binding of approximately 94.5%, bound to albumin and alpha-1 glycoprotein. Fluoxetine readily crosses the blood-brain barrier, with a brain-to-plasma ratio of 2.6:1 in humans. The volume of distribution (Vd) of fluoxetine and its metabolite ranges between 20 to 42 L/kg. Some studies report that fluoxetine has the maximum volume of distribution (Vd) of any SSRI (between 14 and 100 L/kg).<xref ref-type="bibr" rid="article-21850.r8">[8]</xref></p>
        <p><bold>Metabolism:&#x000a0;</bold>Fluoxetine's active metabolite is norfluoxetine, produced when the cytochrome P450 enzyme (CYP2D6) acts on it.&#x000a0;Prescribers must remember that fluoxetine has&#x000a0;several drug-drug interactions due to its metabolism&#x000a0;through the CYP2D6 isoenzyme. Additionally, norfluoxetine can have an inhibitory effect on CYP3A4. Fluoxetine has a half-life of 2 to 4 days, and its active metabolite norfluoxetine has a half-life of 7 to 9 days.<xref ref-type="bibr" rid="article-21850.r9">[9]</xref><xref ref-type="bibr" rid="article-21850.r10">[10]</xref>&#x000a0;Approximately 7% of individuals definitively exhibit poor metabolism of fluoxetine due to reduced activity of CYP2D6.<xref ref-type="bibr" rid="article-21850.r11">[11]</xref></p>
        <p><bold>Elimination:</bold> Fluoxetine and norfluoxetine have long elimination half-lives, leading to the presence of the drug in the body for several weeks, even after stopping its use. This has important implications when discontinuing fluoxetine and prescribing medications that may interact with fluoxetine and norfluoxetine after discontinuation. The metabolism of fluoxetine is extensive, resulting in approximately 2.5% of the administered dose being excreted unchanged in the urine.<xref ref-type="bibr" rid="article-21850.r12">[12]</xref></p>
      </sec>
      <sec id="article-21850.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Fluoxetine should be administered once a day, either in the morning or evening and started at 20 mg daily.&#x000a0;Fluoxetine is only available in an oral formulation as an&#x000a0;oral solution (20 mg/5 mL), tablet (10 mg, 20 mg, 60 mg), capsule (10 mg, 20 mg, 40 mg), and delayed-release capsule (90 mg).</p>
        <p>Fluoxetine is also available in a fixed-dose combination with olanzapine (6&#x000a0;mg olanzapine with 25&#x000a0;mg fluoxetine). Considering that the medication can be efficacious at doses of 5&#x000a0;mg and weighing in on the&#x000a0;adverse&#x000a0;effect profile, it is essential to note that the drug can be administered in a smaller dosage. For an individual with poorly tolerated&#x000a0;adverse effects, the&#x000a0;fluoxetine may be dosed in 10 mg tablets instead of 20 mg to help minimize any&#x000a0;adverse&#x000a0;effects. Generally, 20 mg to 40 mg daily dosing is required to be effective for most individuals.</p>
        <p>It also comes in a delayed-release capsule formulation with a dosage of 90 mg per week. Evidence suggests that the efficacy of the delayed-release formulation (90 mg once weekly) is similar to that of individuals receiving fluoxetine 20 mg daily.&#x000a0;Compared to other SSRIs, fluoxetine is not associated with the emergence of abrupt withdrawal symptoms (eg, sleep disturbances, dysphoria, fever, nausea) seen with other antidepressants due to prolonged half-life.<xref ref-type="bibr" rid="article-21850.r13">[13]</xref><xref ref-type="bibr" rid="article-21850.r14">[14]</xref></p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p><bold>Major depressive disorder: </bold>The typical starting dose of fluoxetine for major depressive disorder (MDD) is 20 mg daily. The maximum recommended dose of fluoxetine for MDD is 80 mg daily.<xref ref-type="bibr" rid="article-21850.r15">[15]</xref>&#x000a0;</p>
        <p><bold>Obsessive-compulsive disorder:</bold> The starting dose of fluoxetine for obsessive-compulsive disorder (OCD) is 20 mg daily. The typical maintenance dose for OCD is 20&#x000a0;to 60 mg.</p>
        <p><bold>Bulimia nervosa: </bold>The<bold>&#x000a0;</bold>American Psychiatric Association guidelines recommend cognitive-behavioral therapy as the primary treatment for adults with bulimia nervosa. If there is minimal or no response to psychotherapy alone within&#x000a0;6 weeks,&#x000a0;prescribing 60 mg of fluoxetine daily is recommended.<xref ref-type="bibr" rid="article-21850.r4">[4]</xref></p>
        <p><bold> Panic disorder: </bold>The typical starting dose of fluoxetine for panic disorder is 10 mg daily. After&#x000a0;1 week, consider increasing the&#x000a0;fluoxetine to 20 mg daily. The maximum recommended dose of fluoxetine for panic disorder is 60 mg daily.</p>
        <p>
<bold>Special Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>In patients with liver cirrhosis, the clearance of fluoxetine and its active metabolite (norfluoxetine) decreases, thus increasing the elimination of half-lives of these substances. Therefore, a lower/less frequent dose of fluoxetine should be used in patients with cirrhosis. In addition, caution is warranted when using fluoxetine in patients with diseases or conditions that could affect its metabolism.</p>
        <p><bold>Renal impairment:&#x000a0;</bold>No dose adjustment of fluoxetine is required in patients with renal impairment.&#x000a0;A study suggests that directly observed, once-weekly fluoxetine could be a feasible and well-tolerated treatment option for hemodialysis patients.<xref ref-type="bibr" rid="article-21850.r16">[16]</xref></p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Fluoxetine&#x000a0;is categorized as Pregnancy Category C medicine. In&#x000a0;the late third trimester, neonates exposed to SSRIs, including fluoxetine, have developed complications requiring prolonged hospitalization, tube feeding, and respiratory support. Complications of temperature instability, feeding difficulty, vomiting, respiratory distress, apnea, cyanosis, hypoglycemia, hypotonia, hypertonia, constant crying, hyperreflexia, tremor, jitteriness, irritability, and seizures are reported. These symptoms could precipitate right at delivery and are consistent with either a drug discontinuation syndrome or a direct toxic effect of SSRIs.The clinician may consider tapering fluoxetine in the third trimester.<xref ref-type="bibr" rid="article-21850.r17">[17]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>As fluoxetine is excreted in human milk, nursing while on fluoxetine is not recommended.<xref ref-type="bibr" rid="article-21850.r17">[17]</xref>&#x000a0;If a woman used fluoxetine during pregnancy, most experts recommend against changing medications while breastfeeding. Otherwise, agents with lower excretion into breast milk may be preferred, especially while nursing a newborn or preterm infant. In addition, the breastfed infant should be monitored for behavioral&#x000a0;adverse effects such as agitation, colic, irritability, poor feeding, and poor weight gain.<xref ref-type="bibr" rid="article-21850.r18">[18]</xref></p>
        <p><bold>Pediatric patients:&#x000a0;</bold>Fluoxetine is FDA-approved for administration in pediatric patients with MDD and OCD. As with other SSRIs, decreased weight gain is associated with administering fluoxetine in children and adolescent patients. The dose for children with MDD and OCD is 10 mg once daily.&#x000a0;According to the AACAP (American Academy of Child and Adolescent Psychiatry), it is recommended to offer selective serotonin reuptake inhibitor (SSRI) medication, particularly fluoxetine, to children and adolescents diagnosed with major depressive disorder. For those who respond positively to acute treatment with fluoxetine, AACAP suggests continuing with fluoxetine alone or combining it with cognitive-behavioral therapy to prevent the relapse or recurrence of major depressive disorder.<xref ref-type="bibr" rid="article-21850.r19">[19]</xref>&#x000a0;</p>
        <p>Extensive metareview study results show that fluoxetine offers a strong risk-benefit ratio compared to other antidepressants in youth. This finding suggests that fluoxetine could be recommended as the initial treatment of choice for depressive disorders in children and adolescents.<xref ref-type="bibr" rid="article-21850.r20">[20]</xref></p>
        <p><bold>Older patients:&#x000a0;</bold>Fluoxetine is effective for major depressive disorder in older patients.<xref ref-type="bibr" rid="article-21850.r21">[21]</xref>&#x000a0;The usual starting dose of fluoxetine is&#x000a0;10 mg once daily; it can be increased to 20 mg as tolerated.</p>
      </sec>
      <sec id="article-21850.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common&#x000a0;adverse&#x000a0;effects reported by adults&#x000a0;include insomnia, nausea, diarrhea, anorexia, dry mouth, headache, drowsiness, anxiety, nervousness, yawning, bruising, seizures, bleeding (rarely), hyperhidrosis, induction of mania, rare activation of suicidal ideation and behavior (especially in teenagers), weight gain/loss, decreased orgasm (anorgasmia and ejaculation latency), muscle weakness, tremors, and pharyngitis.<xref ref-type="bibr" rid="article-21850.r22">[22]</xref><xref ref-type="bibr" rid="article-21850.r23">[23]</xref></p>
        <p>The 5-HT2C antagonism is thought to contribute to the anxiety, insomnia, and agitation patients perceive with fluoxetine. Patients may even have a panic attack with the administration of fluoxetine. Thus, the clinician's responsibility is to educate patients.</p>
        <p>Most&#x000a0;adverse effects are immediate and disappear with time. Thus, waiting for the side effects to subside is best before altering treatment. Most&#x000a0;adverse effects are dose-dependent and time-dependent.&#x000a0;Clinicians must exercise caution against the emergence of agitation or activation, which may indicate a bipolar state and require the addition of a mood stabilizer or an atypical antipsychotic.&#x000a0;Fluoxetine can be activating; if insomnia is present, consider dosing early in the morning. Additionally,&#x000a0;the dose may be reduced if the side effects are too distressing. The patient should be cautioned about adverse effects; if they persist, switching to a different antidepressant may be indicated after a few weeks.<xref ref-type="bibr" rid="article-21850.r24">[24]</xref></p>
        <p>Reversible cerebral vasoconstriction syndrome presenting with a severe headache has been associated with fluoxetine.<xref ref-type="bibr" rid="article-21850.r25">[25]</xref>&#x000a0;A rare case report describes chorea induced by fluoxetine.<xref ref-type="bibr" rid="article-21850.r26">[26]</xref>&#x000a0;Rabbit syndrome&#x000a0;is distinguished by rapid, fine, and rhythmic movements along the vertical axis of the mouth, usually due to antipsychotics. A case report of rabbit syndrome due to fluoxetine in a child with obsessive-compulsive disorder has been reported.<xref ref-type="bibr" rid="article-21850.r27">[27]</xref></p>
        <p>It is best to try another antidepressant before relying on augmentation strategies. This approach can minimize polypharmacy and encourage adherence to psychotropic medications.&#x000a0;Trazodone, mirtazapine, or a hypnotic may be options for insomnia. Mirtazapine may also help with agitation or gastrointestinal&#x000a0;adverse effects. Benzodiazepines may be used to treat anxiety. Bupropion or a phosphodiesterase inhibitor (such as sildenafil) may address sexual dysfunction. Bupropion may also be an option for potential cognitive slowing or apathy seen with fluoxetine.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Fluoxetine inhibits CYP2D6, an enzyme responsible for metabolizing drugs like TCAs, antipsychotics, and antiarrhythmics, and increases the serum concentration of the drugs.<xref ref-type="bibr" rid="article-21850.r12">[12]</xref></p>
        <p><bold>Tricyclic antidepressants:</bold> Using fluoxetine concurrently with tricyclic antidepressants (TCAs) can increase levels of TCAs. This may require adjusting the TCA dosage.</p>
        <p><bold>Antipsychotics:</bold> SSRIs, including fluoxetine, can increase the concentration of haloperidol and clozapine.<xref ref-type="bibr" rid="article-21850.r28">[28]</xref>&#x000a0;Coingestion of aripiprazole and fluoxetine&#x000a0;can predispose to prolongation of the QT interval.<xref ref-type="bibr" rid="article-21850.r29">[29]</xref></p>
        <p><bold>Antiarrhythmic medications:</bold> Simultaneous use of fluoxetine with&#x000a0;Class 1A antiarrhythmic medications like quinidine, procainamide, and Class III antiarrhythmics like amiodarone and sotalol can increase the QT interval.<xref ref-type="bibr" rid="article-21850.r30">[30]</xref></p>
        <p><bold>Benzodiazepines:</bold> Fluoxetine can increase the plasma concentration of alprazolam and diazepam.&#x000a0;Signs of&#x000a0;sedation and impaired psychomotor function should be monitored.<xref ref-type="bibr" rid="article-21850.r31">[31]</xref></p>
        <p><bold>Warfarin:</bold> Among SSRIs,&#x000a0;fluoxetine has&#x000a0;one of the&#x000a0;highest&#x000a0;drug-drug interaction risks with warfarin. Use with caution due to the increased risk of bleeding.&#x000a0;Clinicians should monitor the&#x000a0;PT/INR.<xref ref-type="bibr" rid="article-21850.r32">[32]</xref></p>
        <p><bold>NSAIDs:</bold> Concurrent use of fluoxetine with NSAIDs/aspirin increases the risk of upper gastrointestinal bleeding.<xref ref-type="bibr" rid="article-21850.r33">[33]</xref></p>
        <p><bold>Warfarin:</bold> The concurrent use of fluoxetine with SNRIs or SSRIs and warfarin can increase the anticoagulant effects of warfarin, leading to increased bleeding risk.&#x000a0;Warfarin should be used cautiously, and the PT/INR should be monitored.<xref ref-type="bibr" rid="article-21850.r32">[32]</xref></p>
        <p><bold>Anticonvulsants:</bold> The simultaneous administration of fluoxetine with anticonvulsants like phenytoin or carbamazepine can increase plasma concentration, requiring therapeutic drug monitoring (TDM).<xref ref-type="bibr" rid="article-21850.r34">[34]</xref>&#x000a0;</p>
        <p><bold>Serotonergic agents:</bold> Fluoxetine, especially in combination with other serotonergic medications, can lead to serotonin syndrome. These drugs include triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John's Wort. If any symptoms of serotonin syndrome occur, discontinuing fluoxetine and providing supportive treatment is recommended.<xref ref-type="bibr" rid="article-21850.r35">[35]</xref></p>
      </sec>
      <sec id="article-21850.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to fluoxetine include hypersensitivity to fluoxetine or any component in its formulation.&#x000a0;This drug is also contraindicated with the concurrent use of monoamine oxidase inhibitors (current use of MAOI or within&#x000a0;2 weeks of discontinuing the MAOI) due to the risk of serotonin syndrome.</p>
        <p>Never initiate fluoxetine in a patient receiving linezolid.<xref ref-type="bibr" rid="article-21850.r36">[36]</xref></p>
        <p>Do not give fluoxetine with pimozide or thioridazine due to the risk of QT prolongation.<xref ref-type="bibr" rid="article-21850.r37">[37]</xref></p>
        <p>Use this agent with caution in those with a history of seizures or older patients.&#x000a0;</p>
        <p>
<bold>Boxed Warnings</bold>
</p>
        <p>There is a warning for suicidal ideations in those treated with fluoxetine, especially in younger children and adults 18 to 24 years old.<xref ref-type="bibr" rid="article-21850.r38">[38]</xref>&#x000a0;Parents and caregivers should be advised to closely monitor patients for any changes in behavior within the first 2 months after initiating warfarin therapy.<xref ref-type="bibr" rid="article-21850.r39">[39]</xref></p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p><bold>Pregnancy: </bold>Fluoxetine is not recommended for use during pregnancy. However, depending on the scenario, treatment may be necessary during pregnancy. A risk/benefit analysis merits careful consideration during therapy with fluoxetine in pregnancy. Fluoxetine exposure early in pregnancy may be associated with an increased risk of septal heart defects.<xref ref-type="bibr" rid="article-21850.r40">[40]</xref><xref ref-type="bibr" rid="article-21850.r41">[41]</xref>&#x000a0;</p>
        <p>The use of the medication beyond 20 weeks is associated with pulmonary hypertension in the newborn, although this is definitively not proven. Exposure to fluoxetine late in pregnancy may correlate with the risk of gestational hypertension and preeclampsia. Additionally, trace amounts of the drug may appear in breast milk.</p>
        <p><bold>Electroconvulsive therapy: </bold>Case reports of seizures have been reported in patients administered electroconvulsive therapy (ECT) while on fluoxetine treatment. Caution should be exercised when prescribing fluoxetine to individuals with a history of seizures.<xref ref-type="bibr" rid="article-21850.r42">[42]</xref><xref ref-type="bibr" rid="article-21850.r43">[43]</xref></p>
        <p><bold>Allergic reactions and rash: </bold>If patients develop a rash or any signs of an allergic reaction appear, fluoxetine should be stopped. Fluoxetine-induced Stevens-Johnson syndrome has been reported.<xref ref-type="bibr" rid="article-21850.r44">[44]</xref></p>
        <p><bold>Activation of mania/hypomania: </bold>Patients should be evaluated for bipolar disorder before starting fluoxetine, as it can trigger manic or hypomanic episodes. Close monitoring for any mood changes is necessary during treatment.<xref ref-type="bibr" rid="article-21850.r45">[45]</xref></p>
        <p><bold>Anxiety and insomnia: </bold>Some patients may experience increased anxiety and insomnia while taking fluoxetine.<xref ref-type="bibr" rid="article-21850.r24">[24]</xref></p>
        <p><bold>Angle-closure glaucoma: </bold>Fluoxetine may cause angle-closure glaucoma. Monitor IOP in patients with a history of glaucoma.<xref ref-type="bibr" rid="article-21850.r46">[46]</xref></p>
        <p><bold>Hyponatremia: </bold>In rare cases, fluoxetine has been associated with low sodium levels (hyponatremia) due to the syndrome of inappropriate antidiuretic hormone (SIADH).<xref ref-type="bibr" rid="article-21850.r47">[47]</xref><xref ref-type="bibr" rid="article-21850.r48">[48]</xref></p>
        <p><bold> QT prolongation: </bold>Fluoxetine can prolong the QT interval, possibly leading to torsade de pointes.&#x000a0;The drug should be used cautiously in patients with an increased risk of QT prolongation.<xref ref-type="bibr" rid="article-21850.r37">[37]</xref></p>
        <p><bold>Cognitive impairment: </bold>Fluoxetine can potentially impair cognitive function and motor skills. Per manufacturer labeling, caution should be exercised when performing tasks requiring alertness, such as operating machinery. On the contrary, some studies&#x000a0;suggest&#x000a0;that fluoxetine may enhance cognitive function in patients with dementia. Individual patient assessment and MMSE may be required if there is doubt regarding deteriorating cognition.<xref ref-type="bibr" rid="article-21850.r49">[49]</xref></p>
        <p><bold> Sexual dysfunction: </bold>SSRIs, including fluoxetine, can lead to sexual side effects in both males and females. In males, these may include delayed ejaculation, decreased libido, and erectile dysfunction. This&#x000a0;ADR&#x000a0;can be utilized for&#x000a0;patients&#x000a0;with from premature ejaculation. Females may experience decreased libido or anorgasmia.<xref ref-type="bibr" rid="article-21850.r50">[50]</xref><xref ref-type="bibr" rid="article-21850.r51">[51]</xref></p>
      </sec>
      <sec id="article-21850.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>A thorough assessment of depression and suicidal risk, particularly at the beginning of therapy or when doses are changed, anxiety/panic attacks, social functioning, mania/mood lability, and features of serotonin syndrome.<xref ref-type="bibr" rid="article-21850.r38">[38]</xref><xref ref-type="bibr" rid="article-21850.r52">[52]</xref>&#x000a0;The&#x000a0;PHQ-9&#x000a0;(Patient Health Questionnaire-9) and&#x000a0;HAM-D/HDRS (Hamilton Depression Rating Scale) should be monitored.<xref ref-type="bibr" rid="article-21850.r53">[53]</xref><xref ref-type="bibr" rid="article-21850.r54">[54]</xref><xref ref-type="bibr" rid="article-21850.r55">[55]</xref></p>
        <p>No routine laboratory testing is necessary for healthy individuals. However,&#x000a0;in&#x000a0;older and population-specific patients,&#x000a0;clinicians may order blood glucose and liver function tests. In addition, prescribers may order an ECG for patients with risk factors for QT prolongation and ventricular arrhythmias. Pediatric patients' height and weight should be monitored periodically when receiving fluoxetine.</p>
        <p>The American Society of Regional Anesthesia (ASRA) suggests&#x000a0;a washout period of approximately&#x000a0;5 weeks before interventional spine and pain procedures due to the long half-life of fluoxetine to&#x000a0;decrease the risk of bleeding.<xref ref-type="bibr" rid="article-21850.r56">[56]</xref></p>
      </sec>
      <sec id="article-21850.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Fluoxetine is rarely lethal in monotherapy overdose. However, when taken with alcohol, it may cause ataxia and respiratory depression. The drug may cause serotonin syndrome (clinical constellation of changes in mental status, autonomic instability, and neuromuscular abnormalities) when taken in excessive amounts or combined with other agents that increase serotonin levels.<xref ref-type="bibr" rid="article-21850.r57">[57]</xref><xref ref-type="bibr" rid="article-21850.r58">[58]</xref>&#x000a0;</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>In the case of SSRI overdose, the goal is to provide supportive therapy. This support can be in the form of airway protection, serial ECGs to monitor for cardiotoxicity, administration of benzodiazepines for sedation, and GI decontamination with activated charcoal.&#x000a0;Serotonin syndrome is treatable with the administration of cyproheptadine.<xref ref-type="bibr" rid="article-21850.r59">[59]</xref><xref ref-type="bibr" rid="article-21850.r60">[60]</xref></p>
      </sec>
      <sec id="article-21850.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Fluoxetine is a commonly prescribed antidepressant by physicians and advanced practice practitioners, psychiatrists, and internists, but effective therapy requires the effort of an interprofessional team. When treating&#x000a0;pregnant women during the third trimester with fluoxetine, the prescriber should consider the potential benefits and risks of treatment. In addition, clinicians should consider that women who stopped antidepressant medication while pregnant were more likely to experience a relapse of MDD than women who continued to use antidepressant drugs.</p>
        <p>Nursing staff and&#x000a0;prescribers should monitor children and adolescent patients for suicidal ideation, especially when starting fluoxetine or increasing doses. Nursing staff, particularly those with specialty training in psychiatric health, can counsel patients on proper dosing and administration. For example, it is crucial to educate patients that they should not combine the drug with alcohol or other antidepressants. The patient should have regular follow-ups regarding depression and suicidal thoughts. The pharmacist should verify dosing, especially check for drug interactions, given fluoxetine's extensive list of interactions, and report these to the prescriber if present.</p>
        <p>All interprofessional team members are responsible for monitoring the patient, offering counsel, and noting any patient status changes. If they&#x000a0;observe any issues, they should be documented in the patient's health record for all team members to follow, and the new information should be communicated to other team members so changes can be made if necessary. With close monitoring from all team members, fluoxetine can be an effective drug for numerous psychiatric conditions, including major depression. An interprofessional approach involving open communication between clinicians, specialists, and pharmacists can achieve optimal outcomes related to fluoxetine therapy while mitigating adverse effects.</p>
      </sec>
      <sec id="article-21850.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21850&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21850">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21850/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21850">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21850.s11">
        <title>References</title>
        <ref id="article-21850.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mikocka-Walus</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Prady</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Pollok</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Esterman</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Knowles</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Adjuvant therapy with antidepressants for the management of inflammatory bowel disease.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2019</year>
            <month>Apr</month>
            <day>12</day>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>CD012680</fpage>
            <pub-id pub-id-type="pmid">30977111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dhenain</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>C&#x000f4;t&#x000e9;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Coman</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Serotonin and orthodontic tooth movement.</article-title>
            <source>Biochimie</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>161</volume>
            <fpage>73</fpage>
            <page-range>73-79</page-range>
            <pub-id pub-id-type="pmid">30953672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burch</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Antidepressants for Preventive Treatment of Migraine.</article-title>
            <source>Curr Treat Options Neurol</source>
            <year>2019</year>
            <month>Mar</month>
            <day>21</day>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>18</fpage>
            <pub-id pub-id-type="pmid">30895388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crone</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fochtmann</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Attia</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Boland</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Escobar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fornari</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Golden</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Guarda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jackson-Triche</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Manzo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mascolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pierce</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Riddle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seritan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Uniacke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zucker</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yager</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Medicus</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders.</article-title>
            <source>Am J Psychiatry</source>
            <year>2023</year>
            <month>Feb</month>
            <day>01</day>
            <volume>180</volume>
            <issue>2</issue>
            <fpage>167</fpage>
            <page-range>167-171</page-range>
            <pub-id pub-id-type="pmid">36722117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness and safety of fluoxetine for premature ejaculation: Protocol for a systematic review.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>98</volume>
            <issue>7</issue>
            <fpage>e14481</fpage>
            <pub-id pub-id-type="pmid">30762772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Slee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nazareth</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bondaronek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Freemantle</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis.</article-title>
            <source>Lancet</source>
            <year>2019</year>
            <month>Feb</month>
            <day>23</day>
            <volume>393</volume>
            <issue>10173</issue>
            <fpage>768</fpage>
            <page-range>768-777</page-range>
            <pub-id pub-id-type="pmid">30712879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Naunton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kosari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Christenson</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Treatment Guidelines for PTSD: A Systematic Review.</article-title>
            <source>J Clin Med</source>
            <year>2021</year>
            <month>Sep</month>
            <day>15</day>
            <volume>10</volume>
            <issue>18</issue>
            <pub-id pub-id-type="pmid">34575284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hiemke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>H&#x000e4;rtter</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of selective serotonin reuptake inhibitors.</article-title>
            <source>Pharmacol Ther</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>85</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-28</page-range>
            <pub-id pub-id-type="pmid">10674711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robertson</surname>
                <given-names>OD</given-names>
              </name>
              <name>
                <surname>Coronado</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Sethi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Berk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dodd</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Putative neuroprotective pharmacotherapies to target the staged progression of mental illness.</article-title>
            <source>Early Interv Psychiatry</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>5</issue>
            <fpage>1032</fpage>
            <page-range>1032-1049</page-range>
            <pub-id pub-id-type="pmid">30690898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cao</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zuckerman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rosenblat</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Brietzke</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Subramanieapillai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>McIntyre</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review.</article-title>
            <source>Prog Neuropsychopharmacol Biol Psychiatry</source>
            <year>2019</year>
            <month>Jun</month>
            <day>08</day>
            <volume>92</volume>
            <fpage>109</fpage>
            <page-range>109-117</page-range>
            <pub-id pub-id-type="pmid">30611836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Delavenne</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Magnin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Basset</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Piot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mallouk</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ressnikoff</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Garcin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laporte</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Garnier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mismetti</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Investigation of drug-drug interactions between clopidogrel and fluoxetine.</article-title>
            <source>Fundam Clin Pharmacol</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>683</fpage>
            <page-range>683-9</page-range>
            <pub-id pub-id-type="pmid">23413998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deodhar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rihani</surname>
                <given-names>SBA</given-names>
              </name>
              <name>
                <surname>Darakjian</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Turgeon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Michaud</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Assessing the Mechanism of Fluoxetine-Mediated CYP2D6 Inhibition.</article-title>
            <source>Pharmaceutics</source>
            <year>2021</year>
            <month>Jan</month>
            <day>23</day>
            <volume>13</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">33498694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fava</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Gatti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Belaise</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guidi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Offidani</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review.</article-title>
            <source>Psychother Psychosom</source>
            <year>2015</year>
            <volume>84</volume>
            <issue>2</issue>
            <fpage>72</fpage>
            <page-range>72-81</page-range>
            <pub-id pub-id-type="pmid">25721705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andrade</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Psychotropic Drugs With Long Half-Lives: Implications for Drug Discontinuation, Occasional Missed Doses, Dosing Interval, and Pregnancy Planning.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2022</year>
            <month>Aug</month>
            <day>01</day>
            <volume>83</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">35921503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wagstaff</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Goa</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Once-weekly fluoxetine.</article-title>
            <source>Drugs</source>
            <year>2001</year>
            <volume>61</volume>
            <issue>15</issue>
            <fpage>2221</fpage>
            <page-range>2221-8; discussion 2229-30</page-range>
            <pub-id pub-id-type="pmid">11772132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kauffman</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Dolata</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Figueroa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gunzler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Huml</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pencak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sajatovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sehgal</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Directly Observed Weekly Fluoxetine for Major Depressive Disorder Among Hemodialysis Patients: A Single-Arm Feasibility Trial.</article-title>
            <source>Kidney Med</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>100413</fpage>
            <pub-id pub-id-type="pmid">35386606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larsen</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Damkier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Fenger-Gron</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mikkelsen</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Linde</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Knudsen</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Skaarup</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Videbech</surname>
                <given-names>P</given-names>
              </name>
              <collab>Danish Psychiatric Society</collab>
              <collab>Danish Society of Obstetrics and Gynecology</collab>
              <collab>Danish Paediatric Society</collab>
              <collab>Danish Society of Clinical Pharmacology</collab>
            </person-group>
            <article-title>Use of psychotropic drugs during pregnancy and breast-feeding.</article-title>
            <source>Acta Psychiatr Scand Suppl</source>
            <year>2015</year>
            <issue>445</issue>
            <fpage>1</fpage>
            <page-range>1-28</page-range>
            <pub-id pub-id-type="pmid">26344706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r18">
          <label>18</label>
          <element-citation publication-type="book">
            <chapter-title>Fluoxetine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walter</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Abright</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Bukstein</surname>
                <given-names>OG</given-names>
              </name>
              <name>
                <surname>Diamond</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Keable</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ripperger-Suhler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rockhill</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Major and Persistent Depressive Disorders.</article-title>
            <source>J Am Acad Child Adolesc Psychiatry</source>
            <year>2023</year>
            <month>May</month>
            <volume>62</volume>
            <issue>5</issue>
            <fpage>479</fpage>
            <page-range>479-502</page-range>
            <pub-id pub-id-type="pmid">36273673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solmi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fornaro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ostinelli</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Zangani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Croatto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Monaco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Krinitski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fusar-Poli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Correll</surname>
                <given-names>CU</given-names>
              </name>
            </person-group>
            <article-title>Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects.</article-title>
            <source>World Psychiatry</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>214</fpage>
            <page-range>214-232</page-range>
            <pub-id pub-id-type="pmid">32394557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gutsmiedl</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Krause</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bighelli</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Schneider-Thoma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leucht</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>How well do elderly patients with major depressive disorder respond to antidepressants: a systematic review and single-group meta-analysis.</article-title>
            <source>BMC Psychiatry</source>
            <year>2020</year>
            <month>Mar</month>
            <day>04</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>102</fpage>
            <pub-id pub-id-type="pmid">32131786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mullen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Major depressive disorder in children and adolescents.</article-title>
            <source>Ment Health Clin</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>275</fpage>
            <page-range>275-283</page-range>
            <pub-id pub-id-type="pmid">30397569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bahar</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kamp</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Borgsteede</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Hak</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wilffert</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>84</volume>
            <issue>12</issue>
            <fpage>2704</fpage>
            <page-range>2704-2715</page-range>
            <pub-id pub-id-type="pmid">30248178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wichniak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wierzbicka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wal&#x00119;cka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jernajczyk</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Effects of Antidepressants on Sleep.</article-title>
            <source>Curr Psychiatry Rep</source>
            <year>2017</year>
            <month>Aug</month>
            <day>09</day>
            <volume>19</volume>
            <issue>9</issue>
            <fpage>63</fpage>
            <pub-id pub-id-type="pmid">28791566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manning</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bartow</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dunlap</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kiehl</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kneale</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Reversible Cerebral Vasoconstriction Syndrome Associated With Fluoxetine.</article-title>
            <source>J Acad Consult Liaison Psychiatry</source>
            <year>2021</year>
            <season>Nov-Dec</season>
            <volume>62</volume>
            <issue>6</issue>
            <fpage>634</fpage>
            <page-range>634-644</page-range>
            <pub-id pub-id-type="pmid">34371244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laban</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Larroche</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Comparon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dh&#x000f4;te</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Degos</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Fluoxetine-induced chorea.</article-title>
            <source>Rev Neurol (Paris)</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>177</volume>
            <issue>8</issue>
            <fpage>1010</fpage>
            <page-range>1010-1011</page-range>
            <pub-id pub-id-type="pmid">34148736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naguy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moodliar-Rensburg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Elsori</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Alamiri</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Fluoxetine-Induced "Rabbit Syndrome" in a Child With Juvenile Obsessive-Compulsive Disorder.</article-title>
            <source>Am J Ther</source>
            <string-date>2022 May-Jun 01</string-date>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>e363</fpage>
            <page-range>e363-e364</page-range>
            <pub-id pub-id-type="pmid">32384313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edinoff</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Fort</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Causey</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Burroughs</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Cornett</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Selective Serotonin Reuptake Inhibitors and Clozapine: Clinically Relevant Interactions and Considerations.</article-title>
            <source>Neurol Int</source>
            <year>2021</year>
            <month>Sep</month>
            <day>01</day>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>445</fpage>
            <page-range>445-463</page-range>
            <pub-id pub-id-type="pmid">34564289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <article-title>2021 ACMT Annual Scientific Meeting Abstracts-Virtual.</article-title>
            <source>J Med Toxicol</source>
            <year>2021</year>
            <month>Mar</month>
            <day>31</day>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>93</fpage>
            <page-range>93-153</page-range>
            <pub-id pub-id-type="pmid">33791944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wei</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>QTc prolongation and torsades de pointes due to a coadministration of fluoxetine and amiodarone in a patient with implantable cardioverter-defibrillator: Case report and review of the literature.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>96</volume>
            <issue>49</issue>
            <fpage>e9071</fpage>
            <pub-id pub-id-type="pmid">29245320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dent</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Orrock</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Warfarin-fluoxetine and diazepam-fluoxetine interaction.</article-title>
            <source>Pharmacotherapy</source>
            <year>1997</year>
            <season>Jan-Feb</season>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>170</fpage>
            <page-range>170-2</page-range>
            <pub-id pub-id-type="pmid">9017779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spina</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barbieri</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Cicala</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bruno</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Leon</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clinically relevant drug interactions between newer antidepressants and oral anticoagulants.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-44</page-range>
            <pub-id pub-id-type="pmid">31795773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Abajo</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Montero</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Madurga</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Antidepressants and risk of upper gastrointestinal bleeding.</article-title>
            <source>Basic Clin Pharmacol Toxicol</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>98</volume>
            <issue>3</issue>
            <fpage>304</fpage>
            <page-range>304-10</page-range>
            <pub-id pub-id-type="pmid">16611206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaccara</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Franco</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic Interactions Between Antiseizure and Psychiatric Medications.</article-title>
            <source>Curr Neuropharmacol</source>
            <year>2023</year>
            <volume>21</volume>
            <issue>8</issue>
            <fpage>1666</fpage>
            <page-range>1666-1690</page-range>
            <pub-id pub-id-type="pmid">35611779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Wackernah</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Stimmel</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Serotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants?</article-title>
            <source>J Pharm Pract</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>71</fpage>
            <page-range>71-8</page-range>
            <pub-id pub-id-type="pmid">24153222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mazhar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Akram</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haider</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Overlapping of Serotonin Syndrome with Neuroleptic Malignant Syndrome due to Linezolid-Fluoxetine and Olanzapine-Metoclopramide Interactions: A Case Report of Two Serious Adverse Drug Effects Caused by Medication Reconciliation Failure on Hospital Admission.</article-title>
            <source>Case Rep Med</source>
            <year>2016</year>
            <volume>2016</volume>
            <fpage>7128909</fpage>
            <pub-id pub-id-type="pmid">27433163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tisdale</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management.</article-title>
            <source>Can Pharm J (Ott)</source>
            <year>2016</year>
            <month>May</month>
            <volume>149</volume>
            <issue>3</issue>
            <fpage>139</fpage>
            <page-range>139-52</page-range>
            <pub-id pub-id-type="pmid">27212965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Selph</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>McDonagh</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Depression in Children and Adolescents: Evaluation and Treatment.</article-title>
            <source>Am Fam Physician</source>
            <year>2019</year>
            <month>Nov</month>
            <day>15</day>
            <volume>100</volume>
            <issue>10</issue>
            <fpage>609</fpage>
            <page-range>609-617</page-range>
            <pub-id pub-id-type="pmid">31730312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edinoff</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Akuly</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Hanna</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Ochoa</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Patti</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Ghaffar</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Viswanath</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Urits</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Cornett</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review.</article-title>
            <source>Neurol Int</source>
            <year>2021</year>
            <month>Aug</month>
            <day>05</day>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>387</fpage>
            <page-range>387-401</page-range>
            <pub-id pub-id-type="pmid">34449705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riggin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Frankel</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Moretti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pupco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The fetal safety of fluoxetine: a systematic review and meta-analysis.</article-title>
            <source>J Obstet Gynaecol Can</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>362</fpage>
            <page-range>362-369</page-range>
            <pub-id pub-id-type="pmid">23660045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Lind</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Simeone</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Bobo</surname>
                <given-names>WV</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Riehle-Colarusso</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Polen</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Reefhuis</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Maternal Use of Specific Antidepressant Medications During Early Pregnancy and the Risk of Selected Birth Defects.</article-title>
            <source>JAMA Psychiatry</source>
            <year>2020</year>
            <month>Dec</month>
            <day>01</day>
            <volume>77</volume>
            <issue>12</issue>
            <fpage>1246</fpage>
            <page-range>1246-1255</page-range>
            <pub-id pub-id-type="pmid">32777011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chi</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Effects of Psychotropic Drugs on Seizure Threshold during Electroconvulsive Therapy.</article-title>
            <source>Psychiatry Investig</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>647</fpage>
            <page-range>647-655</page-range>
            <pub-id pub-id-type="pmid">29042890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andrade</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Fluoxetine for Stroke: A Mixed Bag of Outcomes.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2021</year>
            <month>Jun</month>
            <day>08</day>
            <volume>82</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">34106530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agrawal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Almoghrabi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Attar</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Fluoxetine-induced Stevens-Johnson syndrome and liver injury.</article-title>
            <source>J Clin Pharm Ther</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>115</fpage>
            <page-range>115-118</page-range>
            <pub-id pub-id-type="pmid">30296343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akaltun</surname>
                <given-names>&#x00130;</given-names>
              </name>
              <name>
                <surname>Ayaydin</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Fluoxetine-related mania in an adolescent girl diagnosed with selective mutism: A case report.</article-title>
            <source>Asia Pac Psychiatry</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>e12367</fpage>
            <pub-id pub-id-type="pmid">31222962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Costagliola</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Parmeggiani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Semeraro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sebastiani</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure.</article-title>
            <source>Curr Neuropharmacol</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>293</fpage>
            <page-range>293-310</page-range>
            <pub-id pub-id-type="pmid">19587851</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gandhi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shariff</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Al-Jaishi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reiss</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Mamdani</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Hackam</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>McArthur</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Weir</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>AX</given-names>
              </name>
            </person-group>
            <article-title>Second-Generation Antidepressants and Hyponatremia Risk: A&#x000a0;Population-Based Cohort Study of Older Adults.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>69</volume>
            <issue>1</issue>
            <fpage>87</fpage>
            <page-range>87-96</page-range>
            <pub-id pub-id-type="pmid">27773479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seshadri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thalitaya</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Odelola</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Enow</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Antidepressants and Hyponatremia in a patient with Colectomy - a Case Report.</article-title>
            <source>Psychiatr Danub</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>Suppl 3</issue>
            <fpage>610</fpage>
            <page-range>610-614</page-range>
            <pub-id pub-id-type="pmid">28953839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Fluoxetine May Enhance VEGF, BDNF and Cognition in Patients with Vascular Cognitive Impairment No Dementia: An Open-Label Randomized Clinical Study.</article-title>
            <source>Neuropsychiatr Dis Treat</source>
            <year>2021</year>
            <volume>17</volume>
            <fpage>3819</fpage>
            <page-range>3819-3825</page-range>
            <pub-id pub-id-type="pmid">35002241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cooper</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Martyn-St James</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaltenthaler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dickinson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cantrell</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Interventions to treat premature ejaculation: a systematic review short report.</article-title>
            <source>Health Technol Assess</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>21</issue>
            <fpage>1</fpage>
            <page-range>1-180, v-vi</page-range>
            <pub-id pub-id-type="pmid">25768099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jing</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Straw-Wilson</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review.</article-title>
            <source>Ment Health Clin</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>191</fpage>
            <page-range>191-196</page-range>
            <pub-id pub-id-type="pmid">29955469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee-Kelland</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zehra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mappa</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Fluoxetine overdose in a teenager resulting in serotonin syndrome, seizure and delayed onset rhabdomyolysis.</article-title>
            <source>BMJ Case Rep</source>
            <year>2018</year>
            <month>Oct</month>
            <day>08</day>
            <volume>2018</volume>
            <pub-id pub-id-type="pmid">30301727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharp</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The Hamilton Rating Scale for Depression.</article-title>
            <source>Occup Med (Lond)</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>65</volume>
            <issue>4</issue>
            <fpage>340</fpage>
            <pub-id pub-id-type="pmid">25972613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arroll</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Goodyear-Smith</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Crengle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gunn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kerse</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Falloon</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hatcher</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Validation of PHQ-2 and PHQ-9 to screen for major depression in the primary care population.</article-title>
            <source>Ann Fam Med</source>
            <year>2010</year>
            <season>Jul-Aug</season>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>348</fpage>
            <page-range>348-53</page-range>
            <pub-id pub-id-type="pmid">20644190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Rifkin</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Busch</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Bj&#x000f6;rgvinsson</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Validation of the PHQ-9 in a psychiatric sample.</article-title>
            <source>J Affect Disord</source>
            <year>2016</year>
            <month>Mar</month>
            <day>15</day>
            <volume>193</volume>
            <fpage>267</fpage>
            <page-range>267-73</page-range>
            <pub-id pub-id-type="pmid">26774513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Narouze</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Benzon</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Provenzano</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Buvanendran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Andres</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Deer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rauck</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Huntoon</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition): Guidelines From the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain.</article-title>
            <source>Reg Anesth Pain Med</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>225</fpage>
            <page-range>225-262</page-range>
            <pub-id pub-id-type="pmid">29278603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelson</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Erdman</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Booze</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Cobaugh</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Chyka</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Woolf</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Scharman</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Wax</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Manoguerra</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Christianson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Caravati</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Troutman</surname>
                <given-names>WG</given-names>
              </name>
            </person-group>
            <article-title>Selective serotonin reuptake inhibitor poisoning: An evidence-based consensus guideline for out-of-hospital management.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2007</year>
            <month>May</month>
            <volume>45</volume>
            <issue>4</issue>
            <fpage>315</fpage>
            <page-range>315-32</page-range>
            <pub-id pub-id-type="pmid">17486478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Galarneau</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Serotonin Syndrome With Fluoxetine: Two Case Reports.</article-title>
            <source>Ochsner J</source>
            <year>2016</year>
            <season>Winter</season>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>554</fpage>
            <page-range>554-557</page-range>
            <pub-id pub-id-type="pmid">27999518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r59">
          <label>59</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bruggeman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>O'Day</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <chapter-title>Selective Serotonin Reuptake Inhibitor Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">30521236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21850.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barbey</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Roose</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>SSRI safety in overdose.</article-title>
            <source>J Clin Psychiatry</source>
            <year>1998</year>
            <volume>59 Suppl 15</volume>
            <fpage>42</fpage>
            <page-range>42-8</page-range>
            <pub-id pub-id-type="pmid">9786310</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
